Abstract Library

#4219 MAPK and mTOR pathway activation is associated with chemotherapy resistance and a poor prognosis in G3 advanced NENs

Introduction: Neuroendocrine neoplasms (NENs) comprise a broad spectrum of disease ranging from slowly progressive to highly aggressive carcinomas.

Conference:

Presenting Author: Catoya J

Authors: Catoya J, Anton-Pascual B, Farinea G, Modrego A, La Salvia A,

Keywords: NEN, mTOR/MAPK pathway, molecular profiling, platinum-based,

#1737 The Role of MAPK-Signalling in Pancreatic Neuroendocrine Cancer

Introduction: Upon diagnosis, 65% of pNET patients suffer from metastatic or locally unresectable disease. The receptor tyrosine kinase inhibitor sunitinib and the mTOR inhibitor everolimus have set precedence for successful targeted therapies in pNET disease. However, response prediction and treatment alternatives still do not meet medical needs. Recent studies revealed mutations in RAS oncogenes in a fraction of tumours, emphasising a potential role of the MAPK pathway as therapeutic target.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Hoffmann J, Corbett L, Detjen K, Thedieck K, Sers C,

Keywords: pancreatic neuroendocrine tumors, MAPK pathway,

#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors

Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Sasano H

Authors: Iida S, Miki Y, Ono K, Sasano H,

Keywords: neuroendocrine tumors, mTOR inhibitors, MEK inhibitors, combination therapy,